Long-term Documentation of the Utilization of Otezla in Patients With Plaque Psoriasis Under Routine Conditions (LAPIS-Pso)

Trial Profile

Long-term Documentation of the Utilization of Otezla in Patients With Plaque Psoriasis Under Routine Conditions (LAPIS-Pso)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms LAPIS-Pso
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 03 Mar 2017 According to a Celgene Corporation media release, data from this trial will be presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD).
    • 19 Sep 2016 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
    • 11 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top